1 active not recruiting, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow IMGN151: new trials by email Literature Review of IMGN151 trials Research Report on IMGN151
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer | Phase 2 | Recruiting | AbbVie | 377 | 2025-07-30 | 2026-10-01 |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers IMGN151 - Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 1 | Active not recruiting | AbbVie | 256 | 2023-01-11 | 2026-02-20 |
Fallopian Tube Neoplasms (2) · Endometrial Neoplasms (1) · Neoplasms (1) · Recurrence (1) · Uterine Cervical Neoplasms (1)
AbbVie (2)
United States (2) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Ireland (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1)
2023 (1)